Literature DB >> 1990112

Cystic fibrosis, intravenous antibiotics, and home therapy.

L J Hammond, S Caldwell, P W Campbell.   

Abstract

The survival rate of patients with cystic fibrosis has improved considerably in the last 20 years. Although not all of the factors accounting for this change are understood, aggressive nutritional management and treatment of pulmonary exacerbations certainly play a role. Home intravenous (IV) antibiotic delivery for pulmonary exacerbation has proved to be as effective as hospital treatment and offers significant advantages to the patient and family. This article examines the microbiology of pulmonary infections in patients with cystic fibrosis, as well as antimicrobial therapy, methods of IV administration, home IV therapy, and the nurse practitioner's role in this home program in the future.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1990112     DOI: 10.1016/0891-5245(91)90044-q

Source DB:  PubMed          Journal:  J Pediatr Health Care        ISSN: 0891-5245            Impact factor:   1.812


  4 in total

1.  An audit of the effect of intravenous antibiotic treatment on spirometric measures of pulmonary function in cystic fibrosis.

Authors:  J M Bradley; E S Wallace; J S Elborn; J L Howard; M P McCoy
Journal:  Ir J Med Sci       Date:  1999 Jan-Mar       Impact factor: 1.568

Review 2.  Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.

Authors:  Christian Krauth; Noushin Jalilvand; Tobias Welte; Reinhard Busse
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

3.  Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles.

Authors:  Solmaz Ghaffari; Jaleh Varshosaz; Afrooz Saadat; Fatemeh Atyabi
Journal:  Int J Nanomedicine       Date:  2010-12-16

4.  Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis.

Authors:  Maya Graham Pedersen; Søren Jensen-Fangel; Hanne Vebert Olesen; San Deep Prataprao Tambe; Eskild Petersen
Journal:  BMC Infect Dis       Date:  2015-07-27       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.